MEFRUSIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19ClN2O5S2
Molecular Weight	382.883
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(CC1(C)CCCO1)S(=O)(=O)C2=CC(=C(Cl)C=C2)S(N)(=O)=O

InChI

InChIKey=SMNOERSLNYGGOU-UHFFFAOYSA-N

InChI=1S/C13H19ClN2O5S2/c1-13(6-3-7-21-13)9-16(2)23(19,20)10-4-5-11(14)12(8-10)22(15,17)18/h4-5,8H,3,6-7,9H2,1-2H3,(H2,15,17,18)

HIDE SMILES / InChI

Molecular Formula	C13H19ClN2O5S2
Molecular Weight	382.883
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://druginfosys.com/Drug.aspx?drugCode=445&drugName=&type=1
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/7371701 and https://www.ncbi.nlm.nih.gov/pubmed/4779251

Mefruside is a benzene disulfonamide derivative related to the benzothiadiazine or thiazide diuretics. Mefruside is adminisered orally, it is indicated for the treatment of edema and hypertension. It was developed by Bayer A.G. and is sold under the tradename Baycaron.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Urea synthesis 1 Target ID: Urea synthesis Sources: http://www.ncbi.nlm.nih.gov/pubmed/3094538	Inhibitor 8297
Carbonic anhydrase 6 Target ID: CHEMBL2095180 Sources: http://www.ncbi.nlm.nih.gov/pubmed/5459063	Inhibitor 8297		0.73 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: http://druginfosys.com/Drug.aspx?drugCode=445&drugName=&type=1	Primary		Approved 8429	Baycaron Approved Use Mefruside is primarily indicated in conditions like Edema, Hypertension, Oedema.

PubMed

Title	Date	PubMed
Transport of anionic drugs across the basolateral membrane of proximal S2 segments of the rabbit kidney. Inverse relationship between the affinity to the p-aminohippurate transport system and the transport rate.	2002	12572530
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation.	2005 Aug	16044110
A novel study of screening and confirmation of modafinil, adrafinil and their metabolite modafinilic acid under EI-GC-MS and ESI-LC-MS-MS ionization.	2009 Dec	20407560
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

Oral Oedema Adult: 25-50 mg daily, increase if necessary to 75-100 mg. For long-term therapy: 25-50 mg every 2nd or 3rd day. Oral Hypertension Adult: 25-50 mg daily alone or in combination with other antihypertensives, alternate-day maintenance dosage may be used.

Route of Administration: Oral

In Vitro Use Guide

Mefruside (0.3 mM) resulted in 34% Inhibition of urea synthesis from NH4Cl by isolated perfused rat liver

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:39:50 GMT 2023` Edited by `admin` on `Fri Dec 15 16:39:50 GMT 2023`
Record UNII	X1NS9SNS92
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEFRUSIDE

Official Name

English

4-CHLORO-N(SUP 1)-METHYL-N(SUP 1)-(TETRAHYDRO-2-METHYLFURFURYL)-M-BENZENEDISULFONAMIDE

Common Name

English

MEFRUSIDE [MART.]

Common Name

English

MEFRUSIDE [USAN]

Common Name

English

MEFRUSIDE [MI]

Common Name

English

MEFRUSIDE [JAN]

Common Name

English

mefruside [INN]

Common Name

English

Mefruside [WHO-DD]

Common Name

English

BAY 1500

Code

English

BAYCARON

Brand Name

English

1,3-BENZENEDISULFONAMIDE, 4-CHLORO-N(SUP 1)-METHYL-N(SUP 1)-((TETRAHYDRO-2-METHYL-2-FURANYL)METHYL)-

Common Name

English

BAY-1500

Code

English

Classification Tree Code System Code

WHO-VATC

QC03BB05